$ASPI
ASP Isotopes Inc. Stock $aspi

$aspi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000147793224003020 Filed on May 15, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$840.4K	$0.00
YoY Change
Cost Of Revenue	$561.5K	$0.00
YoY Change
Gross Profit	$278.9K	$0.00
YoY Change
Gross Profit Margin	33.18%
Selling, General & Admin	$521.4K	$3.517M
YoY Change	-85.18%	517.1%
% of Gross Profit	186.98%
Research & Development	$215.1K	$207.3K
YoY Change	3.76%	-29.25%
% of Gross Profit	77.14%
Depreciation & Amortization	$103.2K	$0.00
YoY Change
% of Gross Profit	37.01%
Operating Expenses	$6.094M	$3.725M
YoY Change	63.6%	334.0%
Operating Profit	-$5.815M	-$3.725M
YoY Change	56.11%	334.0%
Interest Expense	$13.79K	-$540.00
YoY Change	-2653.33%
% of Operating Profit
Other Income/Expense, Net	-$1.198M	$109.7K
YoY Change	-1191.3%	16403.16%
Pretax Income	-$7.012M	-$3.615M
YoY Change	93.98%	320.36%
Income Tax	$47.62K	$0.00
% Of Pretax Income
Net Earnings	-$6.965M	-$3.615M
YoY Change	92.66%	321.54%
Net Earnings / Revenue	-828.8%
Basic Earnings Per Share	-$0.16	-$0.12
Diluted Earnings Per Share	-$0.16	-$0.12
COMMON SHARES
Basic Shares Outstanding		37.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.89M	$5.082M
YoY Change	370.08%
Cash & Equivalents	$23.89M	$5.082M
Short-Term Investments
Other Short-Term Assets	$1.932M	$688.3K
YoY Change	180.66%
Inventory
Prepaid Expenses
Receivables	$354.1K	$0.00
Other Receivables	$0.00
Total Short-Term Assets	$26.18M	$5.771M
YoY Change	353.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.36M	$8.006M
YoY Change	79.41%
Goodwill	$3.166M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.2K	$133.6K
YoY Change	49.82%
Total Long-Term Assets	$19.21M	$8.836M
YoY Change	117.4%
TOTAL ASSETS
Total Short-Term Assets	$26.18M	$5.771M
Total Long-Term Assets	$19.21M	$8.836M
Total Assets	$45.39M	$14.61M
YoY Change	210.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.223M	$1.287M
YoY Change	72.75%
Accrued Expenses	$1.769M	$408.6K
YoY Change	332.91%
Deferred Revenue
YoY Change
Short-Term Debt	$206.6K	$33.85K
YoY Change	510.25%
Long-Term Debt Due	$60.84K
YoY Change
Total Short-Term Liabilities	$7.332M	$1.996M
YoY Change	267.27%
LONG-TERM LIABILITIES
Long-Term Debt	$22.20M	$0.00
YoY Change
Other Long-Term Liabilities	$1.653M	$698.0K
YoY Change	136.84%
Total Long-Term Liabilities	$1.653M	$698.0K
YoY Change	136.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.332M	$1.996M
Total Long-Term Liabilities	$1.653M	$698.0K
Total Liabilities	$32.36M	$2.694M
YoY Change	1100.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.79M	-$11.17M
YoY Change	175.67%
Common Stock	$486.0K	$373.9K
YoY Change	29.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.52M	$11.91M
YoY Change
Total Liabilities & Shareholders Equity	$45.39M	$14.61M
YoY Change	210.73%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$6.965M	-$3.615M
YoY Change	92.66%	321.54%
Depreciation, Depletion And Amortization	$103.2K	$0.00
YoY Change
Cash From Operating Activities	-$2.970M	-$1.445M
YoY Change	105.57%	401.82%
INVESTING ACTIVITIES
Capital Expenditures	$1.246M	$362.1K
YoY Change	244.1%	-59.72%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.246M	-$362.1K
YoY Change	244.1%	-59.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$20.26M	$4.494M
YoY Change	350.95%	101.24%
NET CHANGE
Cash From Operating Activities	-$2.970M	-$1.445M
Cash From Investing Activities	-$1.246M	-$362.1K
Cash From Financing Activities	$20.26M	$4.494M
Net Change In Cash	$16.05M	$2.687M
YoY Change	497.33%	156.82%
FREE CASH FLOW
Cash From Operating Activities	-$2.970M	-$1.445M
Capital Expenditures	$1.246M	$362.1K
Free Cash Flow	-$4.216M	-$1.807M
YoY Change	133.33%	52.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23890811	usd
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001921865
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48923276	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48598276	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	1821021	usd
CY2024Q1	aspi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate	0	pure
CY2023Q1	aspi	Cash Director Fees CashDirectorFees	240000	usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41555
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	ASP Isotopes Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2618235
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1101 Pennsylvania Avenue NW
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Washington
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	DC
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20004
CY2024Q1	dei	City Area Code CityAreaCode	202
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	756-2245
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01per share
CY2024Q1	dei	Trading Symbol TradingSymbol	ASPI
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51762833	shares
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7908181	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	354083	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	216504	usd
CY2024Q1	aspi	Receivable From Noncontrolling Interests Current ReceivableFromNoncontrollingInterestsCurrent	0	usd
CY2023Q4	aspi	Receivable From Noncontrolling Interests Current ReceivableFromNoncontrollingInterestsCurrent	721548	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1931708	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1664023	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	26176602	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10510256	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14362828	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10712839	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1480266	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1258701	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3165531	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3267103	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	200217	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1793014	usd
CY2024Q1	us-gaap	Assets Assets	45385444	usd
CY2023Q4	us-gaap	Assets Assets	27541913	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2222658	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1111819	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1768767	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1311245	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	206570	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	470396	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	60835	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	61941	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	504425	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	336564	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	882000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	882000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1274091	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1500000	usd
CY2024Q1	aspi	Fair Value Of Shares Issuable FairValueOfSharesIssuable	413000	usd
CY2023Q4	aspi	Fair Value Of Shares Issuable FairValueOfSharesIssuable	0	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7332346	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5673965	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	57398	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	110578	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	22017458	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	185407	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	207092	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1112817	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1066647	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1653000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1653000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	32358426	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8711282	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	485983	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	489233	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42283907	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40567003	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30787385	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23839300	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1464711	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-920982	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	10517794	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	16295954	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	2509224	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	2534677	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13027018	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18830631	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45385444	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27541913	usd
CY2024Q1	us-gaap	Revenues Revenues	840354	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	561484	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	278870	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	0	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	215134	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207334	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5878546	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3517490	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	6093680	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3724824	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5814810	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3724824	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-24343	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-935	usd
CY2024Q1	aspi	Change In Fair Value Of Convertible Notes Payable ChangeInFairValueOfConvertibleNotesPayable	-953710	usd
CY2023Q1	aspi	Change In Fair Value Of Convertible Notes Payable ChangeInFairValueOfConvertibleNotesPayable	0	usd
CY2024Q1	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	-218000	usd
CY2023Q1	aspi	Change In Fair Value Of Share Liability ChangeInFairValueOfShareLiability	110285	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	12188	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	396	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	13788	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1197653	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	109746	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7012463	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3615078	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	47619	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6964844	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3615078	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-16759	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2024Q1	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-6948085	usd
CY2023Q1	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-3615078	usd
CY2024Q1	aspi	Earning Per Share Basic And Diluted Attributable To Shareholders EarningPerShareBasicAndDilutedAttributableToShareholders	-0.16
CY2023Q1	aspi	Earning Per Share Basic And Diluted Attributable To Shareholders EarningPerShareBasicAndDilutedAttributableToShareholders	-0.12
CY2024Q1	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	44561844	shares
CY2023Q1	aspi	Weighted Average Shares Of Common Stock Outstanding Basic And Diluted WeightedAverageSharesOfCommonStockOutstandingBasicAndDiluted	29141525	shares
CY2024Q1	aspi	Net Income Loss Before Allocation To Non Controlling Interests NetIncomeLossBeforeAllocationToNonControllingInterests	-6964844	usd
CY2023Q1	aspi	Net Income Loss Before Allocation To Non Controlling Interests NetIncomeLossBeforeAllocationToNonControllingInterests	-3615078	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-543729	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1003853	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7508573	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4618931	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7530	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7501043	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4618931	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18830631	usd
CY2024Q1	aspi	Retired Unvested Restricted Shares Amount RetiredUnvestedRestrictedSharesAmount	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1713654	usd
CY2024Q1	aspi	Distribution To Noncontrolling Interest Of Variable Interest Entity DistributionToNoncontrollingInterestOfVariableInterestEntity	-8694	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-543729	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6964844	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13027018	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9817461	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4493610	usd
CY2023Q1	aspi	Cancellation Of Common Stock Received In Exchange For Issuance Of Preferred Stock In Subsidiary Amount CancellationOfCommonStockReceivedInExchangeForIssuanceOfPreferredStockInSubsidiaryAmount	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	75570	usd
CY2023Q1	aspi	Issuance Of Restricted Common Stock Amount IssuanceOfRestrictedCommonStockAmount	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2144099	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1003853	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3615078	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11911809	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-6964844	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-3615078	usd
CY2024Q1	us-gaap	Adjustment For Long Term Intercompany Transactions Net Of Tax AdjustmentForLongTermIntercompanyTransactionsNetOfTax	-26387	usd
CY2023Q1	us-gaap	Adjustment For Long Term Intercompany Transactions Net Of Tax AdjustmentForLongTermIntercompanyTransactionsNetOfTax	0	usd
CY2024Q1	us-gaap	Depreciation Depreciation	103210	usd
CY2023Q1	us-gaap	Depreciation Depreciation	0	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1713654	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2144099	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	513748	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2024Q1	aspi	Share Liability For Non Cash Consultant Expense ShareLiabilityForNonCashConsultantExpense	195000	usd
CY2023Q1	aspi	Share Liability For Non Cash Consultant Expense ShareLiabilityForNonCashConsultantExpense	266200	usd
CY2024Q1	aspi	Change In Fair Value Of Shares Liability ChangeInFairValueOfSharesLiability	218000	usd
CY2023Q1	aspi	Change In Fair Value Of Shares Liability ChangeInFairValueOfSharesLiability	-110285	usd
CY2024Q1	aspi	Fair Value Of Convertible Notes Payable Increase Decrease FairValueOfConvertibleNotesPayableIncreaseDecrease	953710	usd
CY2023Q1	aspi	Fair Value Of Convertible Notes Payable Increase Decrease FairValueOfConvertibleNotesPayableIncreaseDecrease	0	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	98658	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	17034	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-49771	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-144392	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2024Q1	aspi	Increase Decrease In Accounts Receivable From Noncontrolling Interest IncreaseDecreaseInAccountsReceivableFromNoncontrollingInterest	699510	usd
CY2023Q1	aspi	Increase Decrease In Accounts Receivable From Noncontrolling Interest IncreaseDecreaseInAccountsReceivableFromNoncontrollingInterest	0	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-299130	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	203959	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-60203	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-34	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-54988	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-388443	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	505480	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	47404	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-101700	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9821	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-270024	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2970469	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1444965	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1245825	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	362056	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1245825	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-362056	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	usd
CY2024Q1	aspi	Repayments Of Distribution To Noncontrolling Interest In Variable Interest Entities RepaymentsOfDistributionToNoncontrollingInterestInVariableInterestEntities	8429	usd
CY2023Q1	aspi	Repayments Of Distribution To Noncontrolling Interest In Variable Interest Entities RepaymentsOfDistributionToNoncontrollingInterestInVariableInterestEntities	0	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20550000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	263141	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	14435	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	506390	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20263995	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4493610	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16047701	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2686589	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-65071	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6561	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7908181	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2389140	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23890811	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5082290	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	364458	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	aspi	Purchase Of Property And Equipment Included In Accounts Payable PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable	1188655	usd
CY2023Q1	aspi	Purchase Of Property And Equipment Included In Accounts Payable PurchaseOfPropertyAndEquipmentIncludedInAccountsPayable	-337158	usd
CY2024Q1	aspi	Payment To Acquire Property And Equipment Included In Other Noncurrent Liabilities PaymentToAcquirePropertyAndEquipmentIncludedInOtherNoncurrentLiabilities	1653000	usd
CY2023Q1	aspi	Payment To Acquire Property And Equipment Included In Other Noncurrent Liabilities PaymentToAcquirePropertyAndEquipmentIncludedInOtherNoncurrentLiabilities	0	usd
CY2024Q1	aspi	Settlement Of Share Liability SettlementOfShareLiability	0	usd
CY2023Q1	aspi	Settlement Of Share Liability SettlementOfShareLiability	75750	usd
CY2022Q4	us-gaap	Share Price SharePrice	4.00
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3800000	usd
CY2024Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	6964844	usd
CY2023Q1	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	3615078	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23890811	usd
CY2024Q1	aspi	Amount Received AmountReceived	gross proceeds of approximately $5,500,000 received in April 2024 through the issuance of common stock from the exercise of warrants
CY2024Q1	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2024Q1	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	886179	usd
CY2023Q4	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	1963000	usd
CY2024Q1	us-gaap	Revenues Revenues	840354	usd
CY2023Q1	us-gaap	Revenues Revenues	0	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7012463	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3615078	usd
CY2024Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	413000	usd
CY2024Q1	aspi	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss FairValueAssetRecurringBasisStillHeldUnrealizedGainLoss	22017458	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	140455	usd
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	669700	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	194540	usd
CY2023	aspi	Hgu hgu	-1004695	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2024Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	195000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	218000	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	413000	usd
CY2024Q1	aspi	Business Acquisition Percentage Of Interests Acquired BusinessAcquisitionPercentageOfInterestsAcquired	0.51	pure
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	27443	usd
CY2023Q4	aspi	Business Acquisition Percentage Of Interests Acquired BusinessAcquisitionPercentageOfInterestsAcquired	0.51	pure
CY2023Q4	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	840354	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	216504	usd
CY2024Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	840354	usd
CY2024Q1	aspi	Revenue Deductions RevenueDeductions	-702775	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	354083	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14502529	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10750546	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	139701	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	37707	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14362828	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10712839	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	587093	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	447295	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1028330	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	845344	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	153344	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18606	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1768767	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1311245	usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	20550000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	513748	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	521423	usd
CY2024Q1	aspi	Fair Value Of Additional Liability FairValueOfAdditionalLiability	21063748	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	22017458	usd
CY2024Q1	aspi	Fair Value Of Convertible Notes Payable Increase Decrease FairValueOfConvertibleNotesPayableIncreaseDecrease	953710	usd
CY2024Q1	aspi	Total Principal And Accrued Interest Of The Convertible Notes TotalPrincipalAndAccruedInterestOfTheConvertibleNotes	21146850	usd
CY2024Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	31142	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	31827	usd
CY2023Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	526282	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0874	pure
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	6748	usd
CY2023Q4	us-gaap	Other Commitment OtherCommitment	1653000	usd
CY2024Q1	us-gaap	Other Liabilities OtherLiabilities	1653000	usd
CY2024Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	6050000	usd
CY2023Q2	us-gaap	Loss Contingency Receivable Proceeds LossContingencyReceivableProceeds	626223	usd
CY2024Q1	us-gaap	Net Investment In Lease Sale NetInvestmentInLeaseSale	2200000	usd
CY2024Q1	us-gaap	Legal Fees LegalFees	78304	usd
CY2022Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	100000	usd
CY2022Q1	aspi	Royalty Percentage On Sale Of Products RoyaltyPercentageOnSaleOfProducts	0.10	pure
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000000	zar
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	354000	usd
CY2023Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	626223	usd
CY2023Q4	aspi	Business Combination Consideration Transferred Cash And Equivalents BusinessCombinationConsiderationTransferredCashAndEquivalents	500000	usd
CY2023Q4	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	1395348	usd
CY2023Q4	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	1895348	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	378152	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	460165	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	184457	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	821926	usd
CY2023Q4	aspi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssets	592304	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities	1248699	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	677163	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	511142	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3205227	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	1895348	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3205227	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3205227	usd
CY2023Q4	aspi	Goodwill Translation Adjustment GoodwillTranslationAdjustment	61876	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3267103	usd
CY2024Q1	aspi	Goodwill Translation Adjustment GoodwillTranslationAdjustment	-101572	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3165531	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48598276	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48923276	shares
CY2024Q1	aspi	Cash Director Fees CashDirectorFees	240000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.603	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0344	pure
CY2024Q1	aspi	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P5Y6M
CY2021Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6000000	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2766000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
CY2024Q1	aspi	Weighted Average Remaining Contractual Term In Years Beginning WeightedAverageRemainingContractualTermInYearsBeginning	P8Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	231000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	35000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.00
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2731000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.90
CY2024Q1	aspi	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P8Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6079530	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1820875	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.88
CY2024Q1	aspi	Weighted Average Remaining Contractual Term In Years Exercisable WeightedAverageRemainingContractualTermInYearsExercisable	P8Y1M6D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4096351	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2731000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.90
CY2024Q1	aspi	Weighted Average Remaining Contractual Term In Years Vested Or Expected To Vest WeightedAverageRemainingContractualTermInYearsVestedOrExpectedToVest	P8Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6079530	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	100000	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	978466	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4489186	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.42
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	364186	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.72
CY2024Q1	aspi	Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeited And Retiredinperiod SharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedAndRetiredinperiod	325000	shares
CY2024Q1	aspi	Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeited And Retiredinperiodweightedaveragegrantdatefairvalue SharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsforfeitedAndRetiredinperiodweightedaveragegrantdatefairvalue	1.19
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3800000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.41
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1713654	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2144099	usd
CY2024Q1	aspi	Net Loss NetLoss	-6948085	usd
	aspi	Net Loss NetLoss	-3615078	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	44561844	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29141525	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2731000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2901000	shares
CY2024Q1	aspi	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	3386076	shares
CY2023Q1	aspi	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	3386076	shares
CY2024Q1	aspi	Restricted Stock RestrictedStock	3800000	shares
CY2023Q1	aspi	Restricted Stock RestrictedStock	7719250	shares
CY2024Q1	aspi	Shares Of Common Stock Equivalents SharesOfCommonStockEquivalents	9917076	shares
CY2023Q1	aspi	Shares Of Common Stock Equivalents SharesOfCommonStockEquivalents	14006326	shares
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007	pure

Files In Submission

Name	View Source	Status
0001477932-24-003020-index-headers.html	Edgar Link	pending
0001477932-24-003020-index.html	Edgar Link	pending
0001477932-24-003020.txt	Edgar Link	pending
0001477932-24-003020-xbrl.zip	Edgar Link	pending
aspi-20240331.xsd	Edgar Link	pending
aspi_10q.htm	Edgar Link	pending
aspi_ex311.htm	Edgar Link	pending
aspi_ex312.htm	Edgar Link	pending
aspi_ex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
aspi-20240331_def.xml	Edgar Link	unprocessable
aspi-20240331_lab.xml	Edgar Link	unprocessable
aspi-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aspi_10q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
aspi-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASPI
ASP Isotopes Inc. Stock $aspi

2024 Q1 Form 10-Q Financial Statement

#000147793224003020 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASPI ASP Isotopes Inc. Stock $aspi

2024 Q1 Form 10-Q Financial Statement

#000147793224003020 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASPI
ASP Isotopes Inc. Stock $aspi